Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- IBKR -2.8%, ALV -2.4%, LBRT -2.3%, OZK -2.3%, CNS -0.5%
Other news:
- RCEL -30.5% (announces CEO transition; Sees Q3 revs below)
- PLX -20.8% (Protalix BioTherapeutics & Chiesi Global Rare Diseases acknowledge CHMP negative opinion on every four week dosing regimen of Elfabrio in the EU)
- SLI -18.4% (prices offering of 29,885,057 common shares at $4.35 per common share)
- BITF -8% (prices offering of $500 mln of 1.375% convertible senior notes due 2031)
- NVO -4.2% (President Trump says the cost of Ozempic will be reduced, according to Reuters)
- LLY -4% (President Trump says the cost of Ozempic will be reduced, according to Reuters)
- LXEO -4% (prices offering of 15,625,000 shares of its common stock at $8.00 per share)
- IMAB -2.6% (strategic transformation to global biotech platform; to pursue Hong Kong IPO; rebrand as NovaBridge Biosciences)
- ORCL -2.6% (Investor day update)
- CWK -2.5% (shareholders approve redomiciliation)
- CRWV -2% (reaffirms rationale behind CORZ acquisition; appoints new CRO)
- BVN -1.9% (Q3 production)
- ROG -1.7% (current Chair to not stand for re-election; appoints new Chair)
- AMRC -1.4% (commercial operations of 50MW battery energy storage system)
- JBL -1.1% (Executive Chairman and certain directors to not seek re-election)